Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of an Outpatient Schedule of Rituximab, Cytarabine, Carboplatin, and Dexamethasone in Relapsed/Refractory Non-Hodgkin Lymphoma. Phase I/II Trial.

NCT03892421 is registered in ClinicalTrials.gov with La Raza Medical Center as lead sponsor.

NCT NCT03892421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03892421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of an Outpatient Schedule of Rituximab, Cytarabine, Carboplatin, and Dexamethasone in Relapsed/Refractory Non-Hodgkin Lymphoma. Phase I/II Trial.
Lead sponsor
La Raza Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
April 5, 2018
Completion date
April 30, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory non-hodgkin lymphoma, relapsed non hodgkin lymphoma